Pacific Biosciences of California (PACB) News Today $1.54 -0.10 (-6.10%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.54 -0.01 (-0.32%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Pacific Biosciences of California (NASDAQ:PACB) Given Neutral Rating at Piper SandlerPiper Sandler reaffirmed a "neutral" rating and set a $2.00 price target (down previously from $2.50) on shares of Pacific Biosciences of California in a report on Thursday.February 21 at 1:13 PM | marketbeat.comAnalysts Issue Forecasts for PACB FY2025 EarningsPacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Pacific Biosciences of California in a research report issued to clients and investors on Tuesday, February 18th. Cantor FitFebruary 21 at 6:47 AM | marketbeat.comFY2025 EPS Estimates for PACB Lowered by Cantor FitzgeraldFebruary 21 at 2:41 AM | americanbankingnews.comPacific Biosciences (PACB) Gets a Hold from Piper SandlerFebruary 20 at 8:49 PM | markets.businessinsider.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Michele Farmer Sells 24,349 SharesPacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) insider Michele Farmer sold 24,349 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $1.88, for a total value of $45,776.12. Following the transaction, the insider now directly owns 187,592 shares of the company's stock, valued at $352,672.96. The trade was a 11.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.February 20 at 5:11 PM | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $45,776.12 in StockFebruary 20 at 5:41 AM | insidertrades.comBrokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target at $2.85February 20 at 1:31 AM | americanbankingnews.comTraders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB)Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) saw some unusual options trading on Tuesday. Investors acquired 31,944 call options on the company. This is an increase of 477% compared to the typical daily volume of 5,533 call options.February 19 at 9:11 PM | marketbeat.comThe Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50The Goldman Sachs Group lowered their price target on Pacific Biosciences of California from $1.75 to $1.50 and set a "neutral" rating for the company in a report on Tuesday.February 19 at 4:20 PM | marketbeat.comPacBio to Participate in TD Cowen's 45th Annual Health Care ConferenceFebruary 19 at 4:05 PM | globenewswire.comTraders Purchase High Volume of Call Options on Pacific Biosciences of California (NASDAQ:PACB)February 19 at 3:23 AM | americanbankingnews.comThe Goldman Sachs Group Has Lowered Expectations for Pacific Biosciences of California (NASDAQ:PACB) Stock PriceFebruary 19 at 1:53 AM | americanbankingnews.comPacific Biosciences of California's (PACB) Overweight Rating Reiterated at StephensFebruary 17, 2025 | americanbankingnews.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by AnalystsPacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and seFebruary 17, 2025 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Upgraded by StockNews.com to "Sell" RatingStockNews.com upgraded Pacific Biosciences of California to a "sell" rating in a research note on Friday.February 15, 2025 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Shares Gap Down - Time to Sell?Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down - Here's WhyFebruary 15, 2025 | marketbeat.comStephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB)Stephens reissued an "overweight" rating and set a $2.50 price objective on shares of Pacific Biosciences of California in a report on Friday.February 15, 2025 | marketbeat.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call TranscriptFebruary 15, 2025 | insidermonkey.comPacific Biosciences of California Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 15, 2025 | finance.yahoo.comPacBio Grants Equity Incentive Award to New EmployeeFebruary 14, 2025 | globenewswire.comPacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Meets EstimatesPacific Biosciences of California (NASDAQ:PACB - Get Free Report) released its earnings results on Thursday. The biotechnology company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). Pacific Biosciences of California had a negative return on equity of 42.71% and a negative net margin of 227.69%. During the same period in the previous year, the business posted ($0.27) EPS.February 14, 2025 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Hits ExpectationsPacific Biosciences of California (NASDAQ:PACB - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). Pacific Biosciences of California had a negative return on equity of 42.71% and a negative net margin of 227.69%.February 14, 2025 | marketbeat.comPacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ...February 14, 2025 | gurufocus.comPacBio (NASDAQ:PACB) Misses Q4 Sales TargetsFebruary 14, 2025 | msn.comQ4 2024 Pacific Biosciences of California Inc Earnings Call TranscriptFebruary 14, 2025 | gurufocus.comPacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comPacific Biosciences of California, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 13, 2025 | seekingalpha.comSumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,178,501 shares of the biotechnology company's stoFebruary 13, 2025 | marketbeat.comPacBio (PACB) Q4 Earnings Report Preview: What To Look ForFebruary 13, 2025 | finance.yahoo.comPacific Biosciences of California Inc (PACB) Q4 2024 Earnings Report Preview: What To ExpectFebruary 12, 2025 | gurufocus.comPacific Biosciences of California (PACB) Expected to Announce Quarterly Earnings on ThursdayPacific Biosciences of California (NASDAQ:PACB) will be releasing earnings after the market closes on Thursday, February 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=661050)February 11, 2025 | marketbeat.comPacific Biosciences of California (PACB) Projected to Post Earnings on ThursdayPacific Biosciences of California (NASDAQ:PACB) will be releasing earnings after the market closes on Thursday, February 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=661050)February 6, 2025 | marketbeat.comPacBio Announces Appointment of David Ruggiero as Head of Global Sales & ServiceFebruary 3, 2025 | globenewswire.comPacific Biosciences of California (NASDAQ:PACB) investors are sitting on a loss of 86% if they invested three years agoFebruary 1, 2025 | uk.finance.yahoo.comPacific Biosciences (NASDAQ:PACB) Stock Quotes, Forecast and News SummaryFebruary 1, 2025 | benzinga.comPacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025January 30, 2025 | globenewswire.comPacBio Announces Appointment of Chris Smith to Board of DirectorsJanuary 30, 2025 | markets.businessinsider.comPacBio Technology Powers Landmark Multiomic Study Published in Nature GeneticsJanuary 29, 2025 | globenewswire.comPacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should KnowJanuary 27, 2025 | msn.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Target Price from BrokeragesShares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rJanuary 26, 2025 | marketbeat.comThe Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.75The Goldman Sachs Group cut their target price on Pacific Biosciences of California from $2.25 to $1.75 and set a "neutral" rating for the company in a research note on Thursday.January 23, 2025 | marketbeat.comPacBio Names Global Institute for Food Security as Canada's First Revio Certified Service ProviderJanuary 23, 2025 | globenewswire.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesPacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve brokerages that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and six have issued a buJanuary 23, 2025 | marketbeat.comCantor Fitzgerald Predicts PACB FY2025 EarningsPacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Pacific Biosciences of California in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecastsJanuary 23, 2025 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Trading 8.5% Higher - Should You Buy?Pacific Biosciences of California (NASDAQ:PACB) Trading 8.5% Higher - Here's WhyJanuary 22, 2025 | marketbeat.comCantor Fitzgerald Comments on PACB FY2025 EarningsPacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Pacific Biosciences of California in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechJanuary 22, 2025 | marketbeat.comPacific Biosciences of California (NASDAQ:PACB) Shares Gap Down - Should You Sell?Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down - Should You Sell?January 16, 2025 | marketbeat.comBarclays PLC Has $1.01 Million Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)Barclays PLC lifted its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Free Report) by 143.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 595,150 shares of the biotechnology company's stoJanuary 15, 2025 | marketbeat.comPacBio and Radboud UMC Announce Remarkable Study Results Using HiFi Long Read Sequencing to Help Advance Rare Disease DiagnosticsJanuary 14, 2025 | globenewswire.comPacBio Announces Preliminary Fourth Quarter and Full Year RevenueJanuary 14, 2025 | globenewswire.com Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address PACB Media Mentions By Week PACB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PACB News Sentiment▼0.120.60▲Average Medical News Sentiment PACB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PACB Articles This Week▼265▲PACB Articles Average Week Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HBIO News Today TMO News Today A News Today MTD News Today WAT News Today ILMN News Today TECH News Today CRL News Today BIO News Today BRKR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PACB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PACB Stock Alerts